Myocardial ischemia and reperfusion are easy to cause a series of injuries

such as arrhythmia

cardiac function decline and myocardial necrosis

which seriously affect the therapeutic effect. Therefore

in-depth study of the pathological mechanism and the prevention and treatment measures of myocardial ischemia-reperfusion injury is the current research hotspot and difficulty. The current mechanism of myocardial ischemia-reperfusion injury focuses on myocardial energy metabolism disorders

oxidative stress

calcium overload

mitochondrial damage

inflammation

and apoptosis. These pathological processes also have complex interactions and mutual promotion relationship

which make clinical control more difficult. Modern western medicine has a limited effect due to its simple target and more adverse reactions. Traditional Chinese medicine(TCM) has many advantages

such as multiple signaling pathways and multiple targets

which have significant effects in the prevention and treatment of cardiovascular diseases. Myocardial ischemia-reperfusion injury is defined as chest apoplexyin TCM. The therapy of ‘reinforcing Qi and activating blood circulation’ is the main therapeutic principle of preventing and treating myocardial ischemia-reperfusion injury in TCM

which is widely applied in clinical practice. Experiments show that TCMs have a intervening effect on multiple pathological mechanisms of myocardial ischemia-reperfusion injury

which can significantly improve myocardial injury and reduce inflammatory infiltration of myocardial cells. Its mechanisms of action include resisting oxidative stress

inhibiting calcium overload

reducing mitochondrial damage

improving myocardial energy metabolism

resisting inflammation

and reducing apoptosis. However

most of the current researches focus on active ingredients of TCM

and there are only a few researches on the therapy of ‘reinforcing Qi and activating blood circulation’. This paper summarizes researches of this therapy on myocardial reperfusion injury

and reviews monomers

drug pairs and group prescriptions

in the expectation of providing a theoretical basis for the clinical application against myocardial ischemia-reperfusion injury.